⌕
Tarsus Pharmaceuticals · TARS · Nasdaq
Tenet 34 · Weak
Compare
$78.20−0.61%At closeTenet 34 · Weak
$78.20−0.48 (−0.61%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Tarsus Pharmaceuticals (TARS) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineGrowing fast: revenue compounds ~67.7%/yr (FY21→FY25), net margin −14.7%. Worth your attention in FY25: Share count (+103.3%) and Capex step-up ($9.9M). Both visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲146.7%
451.4
FY21→FY25CAGR +67.7%/yr
Net income ($M)▲42.5%
−66.4
FY21→FY25CAGR —
Free cash flow ($M)▲73.6%
−22.3
capex stepped upCAGR —
Diluted EPS▲48.2%
−1.59
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+103.3%

20.6mn → 41.8mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex step-up
$9.9M

▲529% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)451.4Revenue−30.7COGS420.7Gross profit−64.3R&D−427.3SG&A−71.0Op income4.6Tax & other−66.4Net income

-15¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Gross Operating Net
1007550250%sector median net margin ~3%FY21FY25

Over this window: gross 96.4% → 93.2%. Net margin -14.7% is below the sector median.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
682,203.0451,360.0182,953.017,447.025,816.057,027.0▲146.7%+67.7%
Cost of revenue
46,330.030,684.012,826.01,593.0955.02,075.0▲139.2%+96.1%
Gross profit
635,873.0420,676.0170,127.015,854.024,861.054,952.0▲147.3%+66.3%
Research & development
747,764.064,322.053,386.050,312.042,624.041,712.0▲20.5%+11.4%
Selling, general & admin
585,829.0427,323.0237,310.0108,700.044,949.025,397.0▲80.1%+102.5%
Total operating expenses
1,331,973.0491,645.0290,696.0159,012.087,573.067,109.0▲69.1%+64.5%
Operating incomefeeds ROC rank
−696,100.0−70,969.0−120,569.0−143,158.0−62,712.0−12,157.0▲41.1%—
Other income, net
5,644.06,610.05,015.07,265.0617.0−1,615.0——
Pretax income
−690,456.0−64,359.0−115,554.0−135,893.0−62,095.0−13,772.0▲44.3%—
Income tax
11,769.02,059.00.00.0−4.055.0—+147.4%
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−702,225.0−66,418.0−115,554.0−135,893.0−62,091.0−13,827.0▲42.5%—
Per share
Diluted EPSbuyback-sensitive
−15.16−1.59−3.07−4.62−2.52−0.67▲48.2%—
Diluted shares (mn)
46.4241.7837.6029.3824.6220.55▲11.1%+19.4%
Margins
Gross margin89th pct in Healthcare
93.2%93.2%93.0%90.9%96.3%96.4%▲0.2pp−3.2pp
Operating margin
−102.0%−15.7%−65.9%−820.5%−242.9%−21.3%▲50.2pp+5.6pp
Net margin10th pct in Healthcare
−102.9%−14.7%−63.2%−778.9%−240.5%−24.2%▲48.4pp+9.5pp
† TTM = trailing four quarters through 2026-09-30.
FY19 – FY20 · 2 more years
Unlock the full history →
2 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-23 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Tarsus Pharmaceuticals' revenue last fiscal year?

Tarsus Pharmaceuticals reported revenue of $451.4M in fiscal 2025, up 146.7% from fiscal 2024.

What was Tarsus Pharmaceuticals' net income?

Tarsus Pharmaceuticals reported net income of −$66.4M in fiscal 2025, a net margin of −14.7%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.